A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Omega 3 fatty acids (Primary) ; Desvenlafaxine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms OmegaDVS
- 27 Dec 2017 Biomarkers information updated
- 09 Mar 2013 New trial record